Predictive Oncology (POAI) AI Stock Analysis

• Market Cap: $7.77M
• Dividend Yield: N/A
• Average Volume (3M): 182.24K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.23
• Revenue Growth: -31.31%
• EPS Growth: 49.27%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): N/A
• Shares Outstanding: 10,222,221
• 10 Day Avg. Volume: 152,081
• 30 Day Avg. Volume: 182,241
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.88
• Enterprise Value/Revenue: 5.10
• Enterprise Value/Gross Profit: 13.82
• Enterprise Value/Ebitda: -0.75
• 1Y Price Target: $0.50
• Price Target Upside: -30.56% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 38 Underperform
• Price Target: $0.50 ▼(-30.56% Downside)

Predictive Oncology's overall stock score is negatively impacted by severe financial instability, poor valuation metrics, and ongoing compliance issues with Nasdaq. The bearish technical indicators further suggest weak market sentiment, contributing to a low score.

Positive Factors

Technology

The proprietary AI platform PEDAL has demonstrated the potential to identify biomarkers in cancer patients, making it an attractive licensing target.

Negative Factors

Financial Performance

Predictive Oncology reported lower than expected revenue for 3Q24, indicating potential financial challenges.

Strategic Uncertainty

The company is undergoing a strategic review, which includes evaluating alternatives like a sale of the company or its assets, creating uncertainty.

Predictive Oncology Business Overview & Revenue Model

Company Description

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

How the Company Makes Money

Predictive Oncology generates revenue through multiple streams, including the sale of its predictive analytics software and services to healthcare providers and pharmaceutical companies. The company also engages in partnerships and collaborations with research institutions and biotech firms, which can lead to licensing agreements and joint ventures that further enhance its revenue potential. Additionally, POAI may receive funding through grants and investments aimed at supporting the development of its technological platform and expanding its product offerings. The combination of these revenue streams, along with the growing demand for personalized medicine solutions, contributes significantly to the company's financial performance.

Predictive Oncology Financial Statement Overview

Summary

Predictive Oncology faces significant financial challenges with declining revenues, negative profit margins, and deteriorating liquidity and solvency metrics. The company must address operational inefficiencies and stabilize its financial position.

Income Statement

The company shows a declining revenue trend with a negative revenue growth rate over the years. Gross profit margin has decreased from 64.7% in 2023 to 49.1% in 2024. The net profit margin is severely low due to net losses. EBIT and EBITDA margins are negative, indicating operational inefficiencies.

Balance Sheet

The balance sheet reveals financial instability with a negative stockholders' equity in 2024, indicating potential solvency issues. Debt-to-equity ratio is not applicable due to negative equity. The equity ratio is negative, reflecting a concerning capital structure.

Cash Flow

Operating cash flows remain negative, highlighting ongoing liquidity challenges. Free cash flow is also negative, but there is a slight improvement in free cash flow growth rate from 2023 to 2024. The operating cash flow to net income ratio is negative, indicating inefficiencies in converting income to cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.62M	1.78M	1.51M	1.42M	1.25M
Gross Profit	797.68K	1.15M	1.00M	933.66K	805.08K
EBITDA	-10.16M	-13.18M	-13.95M	-12.13M	-11.46M
Net Income	-12.20M	-13.98M	-36.21M	-19.66M	-37.70M
Balance Sheet
Total Assets	4.97M	14.42M	25.73M	43.77M	13.06M
Cash, Cash Equivalents and Short-Term Investments	734.67K	8.73M	22.07M	28.20M	678.33K
Total Debt	2.13M	2.86M	180.32K	879.33K	5.87M
Total Liabilities	5.18M	6.15M	3.97M	3.51M	10.42M
Stockholders Equity	-202.61K	8.27M	21.77M	40.27M	2.64M
Cash Flow
Free Cash Flow	-10.98M	-13.49M	-12.85M	-13.17M	-12.62M
Operating Cash Flow	-10.97M	-13.19M	-12.37M	-12.21M	-12.26M
Investing Cash Flow	-9.51K	-302.37K	-475.70K	-10.61M	-167.46K
Financing Cash Flow	3.94M	148.90K	6.72M	50.34M	12.95M

Predictive Oncology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For POAI, the sentiment is Negative. The current price of 0.72 is below the 20-day moving average (MA) of 0.78, below the 50-day MA of 0.85, and below the 200-day MA of 1.02, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 34.40 is Neutral, neither overbought nor oversold. The STOCH value of 8.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for POAI.

Predictive Oncology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NXGL	56 Neutral	$28.23M	―	-62.82%	―	115.94%	17.42%
HBIO	53 Neutral	$23.34M	―	-138.36%	―	-12.24%	-427.45%
RVP	52 Neutral	$23.20M	―	-25.89%	―	-16.05%	-195.28%
Sector *	51 Neutral	$7.35B	-0.20	-44.71%	2.33%	29.35%	-1.02%
EKSO	48 Neutral	$7.81M	―	-96.44%	―	-19.32%	44.73%
POAI	38 Underperform	$7.77M	―	-504.16%	―	-31.31%	49.27%
STSS	―	$6.65M	―	-75.14%	―	―	―

Predictive Oncology Corporate Events

Predictive Oncology Granted Nasdaq Compliance Extension

Predictive Oncology Inc. faced potential delisting from The Nasdaq Capital Market due to non-compliance with the minimum stockholders’ equity and bid price requirements. After a hearing on July 17, 2025, Nasdaq granted the company an extension until December 8, 2025, to meet these requirements, though there is no assurance of compliance.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Sells Eagan Business to DeRoyal

On March 14, 2025, Predictive Oncology entered into an agreement with DeRoyal Industries to sell its Eagan Business, which involved products for automated medical fluid disposal, including the STREAMWAY® product line. This transaction led to the reclassification of the Eagan Business as discontinued operations in the company’s financial statements for 2024 and 2023, reflecting a strategic shift in the company’s focus and potentially impacting its operational and financial landscape.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Faces Nasdaq Non-Compliance Notice

On July 8, 2025, Predictive Oncology received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price had closed below $1.00 for 30 consecutive business days. The company has until January 5, 2026, to regain compliance by achieving a stock price of at least $1.00 for 10 consecutive days. Failure to comply may result in delisting, though the company may be eligible for additional time if it meets other listing standards. Predictive Oncology is actively monitoring its stock price and considering options to address the issue.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Finalizes Stock Exchange Purchase Agreement

Predictive Oncology has entered into a Stock Exchange Purchase Agreement (SEPA) with an accredited investor, allowing the issuance and sale of shares of Common Stock. This transaction is conducted under the exemptions from registration requirements of the Securities Act, potentially impacting the company’s financial operations and investor relations.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.

Predictive Oncology Faces Nasdaq Delisting Notice

On June 9, 2025, Predictive Oncology Inc. received a notice from Nasdaq indicating its failure to meet the minimum stockholders’ equity requirement, leading to a potential delisting from the Nasdaq Capital Market. The company has requested a hearing to appeal this decision, which temporarily halts the delisting process, but there is no guarantee of a favorable outcome. Predictive Oncology is exploring options to regain compliance with Nasdaq’s listing requirements.

The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.